Looks like price is respecting trendline / uptrend.
Price is within range. Needs to break above resistance and stay above for bullish confirmation.
Next target I would imagine a sell off unless FDA approval or some super bullish news is released and it gaps up (possible with these lower cap stocks).
Overall lots of bullish news, Novartis partnership + FDA Fast Track for Remestemcell-L
Price is within range. Needs to break above resistance and stay above for bullish confirmation.
Next target I would imagine a sell off unless FDA approval or some super bullish news is released and it gaps up (possible with these lower cap stocks).
Overall lots of bullish news, Novartis partnership + FDA Fast Track for Remestemcell-L
評論:
Sadly bad news came out and the trend was invalidated - trading just above 78.6% area. I'm in quite a rough drawdown on my positions but you live and you learn. Biotcech stocks are highly risky!
*Not Financial Advice*
*Only Risk What You Can Afford To Lose*
*Just Ideas, Not Investment Advice*
*Trade At Your Own Risk*
*Only Risk What You Can Afford To Lose*
*Just Ideas, Not Investment Advice*
*Trade At Your Own Risk*